about
Radioimmunotherapy with radretumab in patients with relapsed hematologic malignancies.Radiolabeled somatostatin analogues therapy in advanced neuroendocrine tumors: a single centre experience[(18)F]Choline PET/CT and stereotactic body radiotherapy on treatment decision making of oligometastatic prostate cancer patients: preliminary results.FDG-PET in cardiac infections.[(18)F]FDG PET/CT features for the molecular characterization of primary breast tumors.Role of molecular imaging in the management of patients affected by inflammatory bowel disease: State-of-the-art.PET Radiomics in NSCLC: state of the art and a proposal for harmonization of methodology.Differentiated thyroid cancer: a new perspective with radiolabeled somatostatin analogues for imaging and treatment of patients.The role of imaging in the diagnosis of recurrence of primary seminal vesicle adenocarcinoma.Somatostatin receptor positron emission tomography/computed tomography imaging in Merkel cell carcinoma.Detection of a second malignancy in prostate cancer patients by using [(18)F]Choline PET/CT: a case series.ED-B fibronectin expression is a marker of epithelial-mesenchymal transition in translational oncology.Radiolabeled WBC scintigraphy in the diagnostic workup of patients with suspected device-related infections.Added value of 99mTc-HMPAO-labeled leukocyte SPECT/CT in the characterization and management of patients with infectious endocarditis.Radiolabelled leucocyte scintigraphy versus conventional radiological imaging for the management of late, low-grade vascular prosthesis infections.Image acquisition and interpretation criteria for 99mTc-HMPAO-labelled white blood cell scintigraphy: results of a multicentre study.Radiation protection procedures in 131I treatments for thyroid cancer in patients requiring hemodialysis.Radiomics based analysis to predict local control and survival in hepatocellular carcinoma patients treated with volumetric modulated arc therapy.Texture analysis and machine learning to characterize suspected thyroid nodules and differentiated thyroid cancer: Where do we stand?Brief report on the use of radiolabeled somatostatin analogs for the diagnosis and treatment of metastatic small-cell lung cancer patients.Prediction of disease-free survival by the PET/CT radiomic signature in non-small cell lung cancer patients undergoing surgery.Current status of molecular imaging in infections.Miniaturized Radiochemical Purity Testing for 99mTc-HMPAO, 99mTc-HMDP, and 99mTc-Tetrofosmin.Dosimetry for nonuniform activity distributions: a method for the calculation of 3D absorbed-dose distribution without the use of voxel S-values, point kernels, or Monte Carlo simulations.Diagnostic performances of [18f]fluorocholine positron emission tomography in brain tumors.Ability of FDG PET and CT radiomics features to differentiate between primary and metastatic lung lesions.Combined imaging approach to diagnose a meningioma in a patient with prostate and lung cancers.PET/MRI in Infection and Inflammation.The "3M" Approach to Cardiovascular Infections: Multimodality, Multitracers, and Multidisciplinary.[F]FDG-PET/CT texture analysis in thyroid incidentalomas: preliminary resultsEANM guideline for the preparation of an Investigational Medicinal Product Dossier (IMPD)The Use of 18F-FDG-PET/CT in the Diagnostic Workup of CIED Infections: Another PerspectivePET and PET/CT with 68gallium-labeled somatostatin analogues in Non GEP-NETs TumorsComputed tomography based radiomic signature as predictive of survival and local control after stereotactic body radiation therapy in pancreatic carcinoma18F-FDG PET/CT versus bone scintigraphy in the follow-up of gastric cancerComments on the Italian Society of Endocrinology recommendations on post-surgical thyroid ablation in differentiated thyroid cancerCardiac molecular pathways influenced by doxorubicin treatment in miceConcerns About the Risk of Myeloid Malignancies After Radioiodine Therapy in Thyroid CancerConvolutional Neural Networks Promising in Lung Cancer T-Parameter Assessment on Baseline FDG-PET/CT18F-FDG and 68Ga-somatostatin analogs PET/CT in patients with Merkel cell carcinoma: a comparison study
P50
Q33401165-1B7694C8-0BF3-4405-B401-F48DC72E5FFAQ33403035-8C29E6E3-5422-4ECC-843C-7D3DA0CF6588Q36489655-23FF0C18-CCEC-49A4-BD49-070328A0E648Q38125726-A83F0374-EDAB-4E94-9C51-84DE168E623BQ38677216-D0F2461E-6EA9-4960-B81E-15707C139513Q39008712-17E05947-7E63-4561-80B2-37015E94A61CQ39197536-F55AD38F-B70E-479C-B381-15DA817F00BBQ39219435-81EDDA81-0C96-42D9-B4D2-1EEDCCF551BCQ39746082-077E137C-9EEC-4B67-BD23-55B67FFAE613Q40455264-A8F96B11-A6D1-4073-B33D-B0CFF89C2AEBQ40984326-66C6D345-2E26-4FE9-8E8F-F5C7B967930DQ42031689-C22BF8A1-1DBD-4AC7-9297-1ECB0184A2FAQ42248546-DC05F625-CE17-4F29-BF25-D2E18E991BEEQ44106945-CB4641D9-0E35-441A-B141-D4E57FBA75ADQ44393422-9135FAFE-862B-4BD5-B310-C57DA7D516ADQ45344086-AFEAECBE-31D0-4840-9F34-F41A4E36C0A7Q46603799-93836D36-D373-4775-BD63-2E2E761779EBQ47111617-92E6BA15-C803-4F36-AC84-6EF296F07FC3Q47557366-78FC861C-4816-44B0-8C1B-111497118822Q48001532-85491B5D-3879-4CDA-B9D5-DF75BF288E40Q48298566-F96C7245-D72F-4284-B06F-AD54D44D4277Q50108218-990D9F91-E0DC-4B0E-B8DC-B21957418B89Q50530069-BB817939-C1EE-4378-B5FB-1E4E17B6892BQ51235781-2C61F148-19AF-4124-9F9B-C6B626E14664Q52150127-DC14BA5B-234C-445B-8311-30A6F94BFAA1Q52721212-AFE0DDC6-B611-43C9-AB69-DD0041B04DC5Q53065479-F575FFE2-4FEB-42E3-84CA-AB0D645A0FBDQ54240134-2734AF28-73F2-40D6-ABF7-45E03D8BBD11Q54240138-AA1365B7-70F0-48EA-B6F2-C134E32DB245Q56764242-645CB18C-75C9-4AAB-B01E-94E811B3362AQ57757547-25F33D08-A9FC-4B38-AF25-FAD47F2234F0Q58864099-157DA66E-4EA5-4E5D-8FC8-6EAEDBB51E2AQ59074896-D2142FC3-C49A-4DCE-A956-8B996E14EE5EQ61446605-6DF180FF-0535-40E8-9813-771F90A982BDQ61755934-428A95EA-6E91-4967-9514-5B14F5A14F17Q61755938-A4F250BC-4E9A-4933-B168-CB51DA4BC3B0Q64121859-CFCBC0EC-6A42-49C2-8B0D-44E6E93A2A2AQ88556189-9AAC5726-9BB5-47B4-85E5-402141D8371EQ90229739-3A1AC781-1789-44C7-BA3A-939BA413CC0EQ90388470-93AC0EA3-2196-436C-BC5A-47EB11A24479
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Martina Sollini
@ast
Martina Sollini
@en
Martina Sollini
@es
Martina Sollini
@nl
Martina Sollini
@sl
type
label
Martina Sollini
@ast
Martina Sollini
@en
Martina Sollini
@es
Martina Sollini
@nl
Martina Sollini
@sl
prefLabel
Martina Sollini
@ast
Martina Sollini
@en
Martina Sollini
@es
Martina Sollini
@nl
Martina Sollini
@sl
P106
P1153
55241311400
P21
P31
P496
0000-0003-2214-6492